Consensus document
Consensus document on osteoporosis in malesDocumento de consenso de osteoporosis del varón

https://doi.org/10.1016/j.endien.2017.12.003Get rights and content

Abstract

Objective

To provide practical recommendations to assess and treat osteoporosis in males.

Participants

Members of the Bone Metabolism Working Group of the Spanish Society of Endocrinology.

Methods

Recommendations were formulated using the GRADE system (Grading of Recommendations, Assessment, Development, and Evaluation) to describe both the strength of recommendations and the quality of evidence. A systematic search was made in Medline (PubMed) using the following associated terms: “osteoporosis”, “men”, “fractures”, “bone mineral density”, “treatment”, “hypogonadism”, and “prostate cancer”. Papers in English and Spanish with publication date before 30 August 2017 were included. Current evidence for each disease was reviewed by 2 group members. Finally, recommendations were discussed in a meeting of the working group.

Conclusions

The document provides evidence-based practical recommendations for diagnosis, assessment, and management of osteoporosis in men and special situations such as hypogonadism and prostate cancer.

Resumen

Objetivo

Proporcionar unas recomendaciones prácticas para la evaluación y tratamiento de la osteoporosis del varón.

Participantes

Miembros del Grupo de Metabolismo Mineral de la Sociedad Española de Endocrinología y Nutrición.

Métodos

Las recomendaciones se formularon de acuerdo con el sistema Grading of Recommendations, Assessment, Development and Evaluation (GRADE) para establecer tanto la fuerza de las recomendaciones como el grado de evidencia. Se realizó una búsqueda sistemática en Medline de la evidencia disponible sobre la osteoporosis del varón usando las siguientes palabras claves asociadas: osteoporosis, men, fractures, bone mineral density, treatment, hypogonadism y prostate cancer. Se revisaron artículos escritos en inglés y español con fecha de inclusión hasta el 30 de agosto del 2017; cada tema fue revisado por 2 personas del grupo. Tras la formulación de las recomendaciones, estas se discutieron en una reunión conjunta del grupo de trabajo.

Conclusiones

El documento establece unas recomendaciones prácticas basadas en la evidencia acerca del diagnóstico, evaluación y tratamiento de la osteoporosis del varón y situaciones especiales como el hipogonadismo y el tratamiento con terapia de déficit androgénico en el carcinoma de próstata.

Introduction

Osteoporosis is defined as a systemic skeletal disorder characterized by low bone mass and impaired bone microarchitecture, with a resultant increase in bone fragility and a greater susceptibility to fractures.1, 2 The densitometric definition of osteoporosis of the World Health Organization also applies to males.3, 4

Male osteoporosis is a condition with a high prevalence of secondary osteoporosis (40–60% in males aged less than 70 years) (Table 1).2, 4, 5 In Spain, the estimated prevalence rates of osteoporosis in males are 8.1% and 11.3% in those older than 50 and 70 years respectively.2, 6 Osteoporotic fractures in males are characterized by greater morbidity and mortality as compared to females.6, 7

The recommendations were formulated according to the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system.8 In terms of the strength of the recommendation, a distinction is made between strong recommendations, expressed as “We recommend” and number 1, and weak recommendations, expressed as “We suggest” and number 2. The quality of evidence is expressed using symbols: ⊕, indicates very low evidence; ⊕⊕, low evidence; ⊕⊕⊕, moderate evidence; and ⊕⊕⊕⊕, high evidence.8 A systematic search was made in Medline for the evidence available regarding osteoporosis in males and the title of each chapter. Articles written in English and Spanish published up to August 30, 2017 were reviewed. Each topic was reviewed by two members of the group. Once the recommendations had been formulated, they were discussed at a joint meeting of the Working Group.

Section snippets

Recommendation

  • -

    We recommend that an accurate clinical history be taken and a detailed physical examination be conducted. Relevant data include drugs used, chronic diseases, alcohol consumption, smoking, any history of falls or fractures in adult age, and any family history of osteoporosis or hip fracture in first-degree relatives. Physical examination should include patient height, a comparison with his maximum height and dorsal kyphosis and the body mass index. Signs suggesting secondary causes should be

Recommendation

  • -

    We suggest, as general measures, the practice of regular physical activity, smoking cessation, the avoidance of excess alcohol consumption, adequate calcium intake, and adequate 25-hydroxyvitamin D levels (2⊕⊕OO).

  • -

    We recommend specific actions and advice to prevent falls in elderly patients (1⊕OOO).

Evidence

General measures for fracture prevention are important in the treatment of osteoporosis. However, their effect on fracture reduction has not been assessed.12, 17 The prevention of falls is an

Recommendation

  • -

    We suggest that the intervention thresholds for females should also be applied to males: T-scores ≤2.5 SD or the presence of fragility fractures (2⊕⊕OO).

  • -

    We suggest the use of oral bisphosphonates (alendronate or risedronate) as first-line agents and zoledronate, denosumab, or teriparatide in specific situations (2⊕⊕OO).

Evidence

Very few studies with specific data for males are available. However, there is no evidence suggesting that results associated with drug treatment are different in males and

Recommendation

  • -

    We suggest the measurement of lumbar and femoral BMD using DXA every 1–2 years in males on antiosteoporotic treatment (2⊕⊕OO).

  • -

    We suggest the measurement of BRMs (C-terminal telopeptide of type I collagen [CTX] or amino-terminal propeptide of type I collagen [PINP]), especially in patients with inadequate response to treatment or suspected low treatment compliance (2⊕OO).

Evidence

The Endocrine Society suggests the measurement of BMD by DXA every 1–2 years and a longer interval after the densitometric

Recommendation

  • -

    We recommend the measurement of BMD in patients with hypogonadism (1⊕⊕⊕O).

  • -

    We suggest that for males at a high risk of fracture who are on treatment with testosterone, an effective drug for reducing the risk of fracture (bisphosphonates, denosumab, or teriparatide) should be added (2⊕OOO).

  • -

    We suggest treatment with testosterone in males at a high risk of fracture and baseline total testosterone levels <200 ng/dL if the use of other drugs for osteoporosis is contraindicated (2⊕⊕OO).

Evidence

Any disease

Conflicts of interest

Manuel Muñoz Torres is an advisory board member (Amgen, UCB, Shire) and lecturer (Amgen, Lilly).

Guillermo Martínez Díaz-Guerra is an advisory board member (Lilly, Amgen) and lecturer (Lilly, Amgen).

Esteban Jódar Gimeno is an advisory board member (Amgen, UCB, Shire) and lecturer (Amgen, Lilly).

The following authors reported no conflicts of interest regarding the preparation of this document: Verónica Ávila Rubio, Mariela Varsavsky, Antonía García Martín, Manuel Romero Muñoz, Antonio Becerra,

References (66)

  • M.R. Smith et al.

    Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer

    J Urol

    (2003)
  • L.H. Klotz et al.

    A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study

    Eur Urol

    (2013)
  • R. Reyes-García et al.

    Update of recommendations for evaluation and treatment of osteoporosis associated to endocrine and nutritional conditions

    Endocrinol Nutr

    (2015)
  • A. Qaseem et al.

    Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians

    Ann Intern Med

    (2017)
  • M. Muñoz-Torres et al.

    Osteoporosis. Definición. Epidemiología

    Rev Osteoporos Metab Miner

    (2010)
  • Assessment of fracture risk and its application to screening for posmenopausal osteoporosis

    World Health Organ Tech Rep Ser

    (1994)
  • S. Nayak et al.

    Osteoporosis treatment efficacy for men: a systematic review and meta-analysis

    J Am Geriatr Soc

    (2017)
  • Osteoporosis in men: why change needs to happen

    (2017)
  • D. Atkins et al.

    Grading quality of evidence and strength of recommendations

    BMJ

    (2004)
  • N.B. Watts et al.

    Osteoporosis in men: an Endocrine Society clinical practice guideline

    J Clin Endocrinol Metab

    (2012)
  • E.S. Siris et al.

    Osteoporos Int

    (2014)
  • S.R. Cummings et al.

    BMD and risk of hip and nonvertebral fractures in older men: a prospective study and comparison with older women

    J Bone Miner Res

    (2006)
  • U.S. Preventive Services Task Force

    Screening for osteoporosis: U.S. Preventive Services Task Force recommendation statement

    Ann Intern Med

    (2011)
  • National Osteoporosis Foundation

    2014 clinician's guide to prevention and treatment of osteoporosis

    (2017)
  • Centre for Metabolic Bone Diseases

    FRAX WHO fracture risk assessment tool

    (2017)
  • A. Ross et al.

    Dietary reference intakes for calcium and vitamin D

    (2011)
  • M.R. Law et al.

    A meta-analyisis of cigarette smoking, bone mineral density and risk of hip fracture: recognition of a major effect

    BMJ

    (1997)
  • M. Naves Diaz

    Osteoporos Int

    (1997)
  • L.D. Gillespie et al.

    Interventions for preventing falls in the elderly

    Cochrane Database Syst Rev

    (2001)
  • F. Cosman et al.

    Clinician's guide to prevention and treatment of osteoporosis

    Osteoporos Int

    (2014)
  • E. Orwoll et al.

    Alendronate for the treatment of osteoporosis in men

    N Engl J Med

    (2000)
  • A.M. Sawka et al.

    Does alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women

    BMC Musculoskelet Disord

    (2005)
  • Z. Xu

    Alendronate for the treatment of osteoporosis in men: a meta-analysis of randomized controlled trials

    Am J Ther

    (2017)
  • Cited by (0)

    Please cite this article as: Varsavsky M, Romero Muñoz M, Ávila Rubio V, Becerra A, García Martín A, Martínez Díaz-Guerra G, et al. Documento de consenso de osteoporosis del varón. Endocrinol Nutr. 2018;65:9–16.

    View full text